| T9601 |
Tepotinib hydrochloride(1 : x)
|
1103508-80-0
|
98%
|
|
|
Tepotinib hydrochloride(1 : x) is an orally bioavailable, mesenchymal-epithelial transition (MET) TKI developed mainly for selected NSCLC patients with METex14 s...
|
| T37596 |
Terevalefim
|
1070881-42-3
|
98%
|
|
|
Terevalefim (ANG-3777) is an hepatocyte growth factor (HGF) mimetic. Terevalefim selectively activates the c-Met receptor.
|
| T11162 |
EGFR-IN-8
|
2407957-87-1
|
98%
|
|
|
EGFR-IN-8, a dual inhibitor targeting both EGFR and c-Met, shows potential as a promising candidate for further development in treating EGFR TKI-resistant NSCLC....
|
| T77437 |
Telisotuzumab
|
1781223-80-0
|
98%
|
|
|
Telisotuzumab(ABT-700) is a humanized recombinant antibody targeting the therapeutic hepatocyte growth factor receptor (MET) with high affinity for c-Met.Telisot...
|
| T76780 |
Onartuzumab
|
1133766-06-9
|
98%
|
|
|
Onartuzumab (MetMAb) is a humanized anti-tyrosine kinase c-MET monovalent monoclonal antibody.Onartuzumab has antitumor activity with inhibitory effects on HGF b...
|
| T76758 |
Rilotumumab
|
872514-65-3
|
98%
|
Rilotumumab
|
|
Rilotumumab (AMG 102) is a monoclonal antibody targeting hepatocyte growth factor that inhibits HGF/ MET-driven signaling. Rilotumumab has antitumor effects and ...
|
| T76743 |
Emibetuzumab
|
1365287-97-3
|
98%
|
Emibetuzumab
|
|
Emibetuzumab is a potent humanized bivalent MET antibody (IgG4 type). Emibetuzumab has antitumor activity, inhibition of HGF-dependent and independent MET pathwa...
|
| T6154 |
SU11274
|
658084-23-2
|
98%
|
|
|
SU11274 (Met Kinase Inhibitor)(IC50=10 nM) is a specific Met inhibitor. It shows no significant effects on PGDFRβ, EGFR or Tie2.
|
| T5656 |
(±)-Norcantharidin
|
29745-04-8
|
|
|
|
(±)-Norcantharidin (Endothall anhydride) is a synthetic anticancer compound which is a dual inhibitor for c-Met and EGFR in human colon cancers.
|
| T77620 |
LMTK3-IN-1
|
2764850-23-7
|
100%
|
|
|
Lmtk3-in-1 is a potent ATP-competitive lemur tyrosine kinase 3 (LMTK3) (Kd=2.5 μM) inhibitor that degrades LMTK3 through the ubiquitin proteasome pathway. LMTK3-...
|
| T7787 |
BMS817378
|
1174161-69-3
|
100%
|
|
|
BMS817378 is a potent and selective inhibitor of MET(IC50 : 1.7 nM).
|
| T4260 |
Capmatinib 2HCl
|
1197376-85-4
|
100%
|
|
|
Capmatinib 2HCl (INC-280 2HCl) is a novel, ATP-competitive inhibitor of c-MET kinase with an IC50 with 0.13 nM.Capmatinib 2HCl exhibits picomolar enzymatic poten...
|
| T5414 |
Glumetinib
|
1642581-63-2
|
100%
|
|
|
Glumetinib (SCC244) (SCC 244) is a novel potent and selective inhibitor of c-Met kinase (IC50: 0.42 nM).
|
| T2208 |
Bacitracin Zinc
|
1405-89-6
|
63.98%
|
|
|
Bacitracin Zinc is an antibiotic that interferes with the dephosphorylation of C55-isoprenyl pyrophosphate, interference for inhibition of cleavage of Tyr from M...
|
| T5677 |
SAR125884 hydrochlorid (1116743-46-4(free base))
|
T5677
|
95%
|
|
|
SAR125844 is a potent and selective MET kinase inhibitor with a favorable preclinical toxicity profile,(IC50=4.2 nM).
|
| T67859 |
C-Met inhibitor D9
|
299405-67-7
|
97%
|
|
|
C-Met inhibitor D9 is a c-Met kinase inhibitor.
|
| T39507L |
Fosgonimeton acetate
|
|
97.05%
|
|
|
Fosgonimeton acetate is an agonist of hepatocyte growth factor (HGF).
|
| T5164 |
Cabozantinib hydrochloride
|
1817759-42-4
|
97.09%
|
|
|
Cabozantinib hydrochloride (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt4 (IC50s: 0.035, 1.3, 4.6, 7 and 6 nM...
|
| T6095 |
JNJ-38877605
|
943540-75-8
|
97.15%
|
|
|
JNJ-38877605 is an ATP-competitive c-Met inhibitor (IC50: 4 nM), 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases.
|
| TQ0219 |
MK-8033
|
1001917-37-8
|
97.16%
|
|
|
MK-8033 is a new and selective dual ATP competitive c-Met/Ron inhibitor (IC50: 1 nM Wt c-Met).
|
